Michael P. Neary
Hoofd Techniek/Wetenschap/O&O bij Promentis Pharmaceuticals, Inc.
Profiel
Michael P.
Neary is currently the Director of Research & Development at Promentis Pharmaceuticals, Inc. He previously worked as a Principal at Roche Madison, Inc. Neary received his undergraduate degree from the University of Wisconsin.
Actieve functies van Michael P. Neary
| Bedrijven | Functie | Begin |
|---|---|---|
Promentis Pharmaceuticals, Inc.
 Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Hoofd Techniek/Wetenschap/O&O | 01-01-2010 |
Eerdere bekende functies van Michael P. Neary
| Bedrijven | Functie | Einde |
|---|---|---|
Roche Madison, Inc.
 Roche Madison, Inc. Pharmaceuticals: MajorHealth Technology Roche Madison, Inc. provides gene transfer technologies to the pharmaceutical industry. The company was founded in 1995 by Jon Wolff, James Hagstrom and Vladimir Budker and is headquartered in Madison, WI. | Corporate Officer/Principal | - |
Opleiding van Michael P. Neary
| University of Wisconsin | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Health Technology |
Roche Madison, Inc.
Roche Madison, Inc. Pharmaceuticals: MajorHealth Technology Roche Madison, Inc. provides gene transfer technologies to the pharmaceutical industry. The company was founded in 1995 by Jon Wolff, James Hagstrom and Vladimir Budker and is headquartered in Madison, WI. | Health Technology |
